Literature summary for 2.7.11.1 extracted from

Chai, J.; Wang, S.; Han, D.; Dong, W.; Xie, C.; Guo, H.
MicroRNA-455 inhibits proliferation and invasion of colorectal cancer by targeting RAF proto-oncogene serine/threonine-protein kinase (2015), Tumor Biol., 36, 1313-1321 .

No PubMed abstract available

Search for more literature for 2.7.11.1

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
colon cancer cell	-	Homo sapiens	-
SW-480 cell	-	Homo sapiens	-

Synonyms

Synonyms	Comment	Organism
RAF proto-oncogene serine/threonine-protein kinase	-	Homo sapiens
RAF1	-	Homo sapiens

Expression

Organism	Comment	Expression
Homo sapiens	overexpression of microRNA miR-455 decreases protein expression of RAF proto-oncogene serine/threonine-protein kinase (RAF1) but has no effect on mRNA level. miR-455 regulates RAF1 expression directly. Overexpression of miR-455 significantly inhibits the proliferation and the invasion of SW480, but has no effect on apoptosis. Overexpression of RAF1 partially reverses the inhibitory effect of miR-455 on the growth and the invasion of SW480	down

General Information

General Information	Comment	Organism
additional information	overexpression of microRNA miR-455 decreases protein expression of RAF proto-oncogene serine/threonine-protein kinase (RAF1) but has no effect on mRNA level. miR-455 regulates RAF1 expression directly. Overexpression of miR-455 significantly inhibits the proliferation and the invasion of SW480, but has no effect on apoptosis. Overexpression of RAF1 partially reverses the inhibitory effect of miR-455 on the growth and the invasion of SW-480. MicroRNAs (miRNAs) are a class of small (18-25 nucleotides long) noncoding RNAs with important posttranscriptional regulatory functions. miRNAs play important roles in various physiological and pathological processes including carcinogenesis in various solid cancers including colorectal cancer	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)